References
- Schols AM, Broekhuizen R, Weling-Scheepers CA, Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005 Jul; 82(1):53–59.
- Agusti AG, Soriano JB. COPD as a systemic disease. COPD 2008; 5:133–138.
- Rabe KF, Hurd S, Anzueto A, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Gold executive summary. Am J Respir Crit Care Med 2007; 176:532–555.
- Kjensli A, Mowinckel P, Ryg MS, Low bone mineral density is related to severity of chronic obstructive pulmonary disease. Bone 2007; 40:493–497.
- Vrieze A, de Greef MH, Wy'kstra PJ, Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int 2007; 18:1197–1202.
- Duckers JM, Evans BA, Fraser WD, Low bone mineral density in men with chronic obstructive pulmonary disease. Respiratory Research 2011; 12:101.
- Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med. 2003 Jan; 114(1):10–14.
- Leech JA, Dulberg C, Kellie S, Relationship of lung function to severity of osteoporosisin women. Am Rev Respir Dis 1990 Jan; 141(1): 68–71.
- Bolton CE, Stone MD, Edwards PH, Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chron Respir Dis 2009; 6(2): 81–87.
- Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, Monroe HR, Sahab ZJ, Sang QX. Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol. 2008 Feb; 9(1):34–46.
- Tanaka H, Miyazaki N, Oashi K, Sputum matrix metalloproteinase-9:tissue inhibitor of metalloproteinase-1 ratio in acute asthma. J Allergy Clin Immunol 2000; 105:900–905.
- Engsig MT, Chen QJ, Vu TH, Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 2000; 151(4):879–889.
- Hill PA, Murphy G, Docherty AJ, The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J Cell Sci 1994 Nov; 107 (Pt 11)3055–3064.
- McLean RR. Proinflammatory Cytokines and Osteoporosis. Current Osteoporosis Reports 2009; 7:134–139.
- Pinto-Plata V, Casanova C, Müllerova H, Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. Respir Res 2012; 13(1):71.
- Bon JM, Leader JK, Weissfeld JL, The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PLoS One 2009 Aug 31; 4(8):e6865.
- Mundy GR. Osteoporosis and Inflammation. Nutrition Reviews 2007; 65:S147–S151
- Ragab AA, Nalepka JL, Bi Y, Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. Am J Physiol Cell Physiol 2002; 283:C679–687.
- Kwan TS, Padrines M, Théoleyre S, IL-6, RANKL, TNF-α/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004; 15:49–60.
- Simonet WS, Lacey D, Dunstan C, Osteoprogerin:a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309–319.
- Hacievliyagil SS, Gunen H, Mutlu LC, Karabulut AB, Temel I. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir Med 2006 May; 100(5):846–854.
- Xie B, Laouar A, Huberman E. Autocrine regulation of macrophage differentiation and 92-kDa gelatinase production by tumor necrosis factor-alpha via alpha5 beta1 integrin in HL-60 cells. J Biol Chem 1998 May 8; 273(19):11583–11588.
- Xie B, Laouar A, Huberman E. Fibronectin-mediated cell adhesion is required for induction of 92-kDa type IV collagenase/gelatinase (MMP-9) gene expression during macrophage differentiation. The signaling role of protein kinase C-beta. J Biol Chem 1998 May 8; 273(19):11576–11582.
- Jones PW, Harding G, Berry P, Development and first validation of the COPD Assessment Test. Eur Respir J 2009 Sep; 34(3):648–654.
- Kanis JA, Melton LJ 3rd, Christiansen C, The diagnosis of osteoporosis.J Bone Miner Res. 1994 Aug; 9(8):1137–1141.
- Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 2009; 103(8):1231–1238.
- Olafsdottir IS, Janson C, Lind L, Hulthe J, Gunnbjornsdottir M, Sundstrom J. Serum levels of matrix metalloproteinase-9, tissue inhibitors of metalloproteinase-1 and their ratio are associated with impaired lung function in the elderly: a population-based study. Respirology 2010; 15(3):530–535.
- Qin J, Yang NL. Relationship between serum matrix metalloproteinase-9 and tissue inhibitors of metalloproteinase-1 and bone mineral density in postmenopausal women. Chin J Osteoporos 2008; 14(4):245–248.
- Nyman JS, Lynch CC, Perrien DS, Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone. J Bone Miner Res 2011 Jun; 26(6):1252–1260.
- Bon JM, Zhang Y, Duncan SR, Pilewski JM, Zaldonis D, Zeevi A, McCurry KR, Greenspan SL, Sciurba FC. Plasma inflammatory mediators associated with bone metabolism in COPD. COPD 2010 Jun; 7(3):186–191.
- Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004 Jul; 59(7):574–580.
- Kochetkova EA, Ugaĭ LG, Maĭstrovskaia IuV, Buria KA, Nevzorova VA. Role of matrix metalloproteinase-9 in the pathogenesis of osteoporosis in patients with chronic obstructive pulmonary disease. Ter Arkh 2012; 84(8):37–40.
- Hozumi A, Nishimura Y, Nishiuma T, Kotani Y, Yokoyama M. Induction of MMP-9 in normal human bronchial epithelial cells by TNF-alpha via NF-kappa B-mediated pathway. Am J Physiol Lung Cell Mol Physiol 2001 Dec; 281(6):L1444–1452.
- Bai P, Sun Y, Jin J, Hou J, Li R, Zhang Q, Wang Y. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respir Res 2011 Dec 16; 12:157.
- Nakamura M, Udagawa N, Matsuura S, Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 2003; 144(12):5441–5449.
- Nakamichi Y, Udagawa N, Kobayashi Y, Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J Immunol 2007; 178(1):192–200.
- Khosla S. Minireview: the OPG/RANKL/RANK system.Endocrinology 2001 Dec; 142(12):5050–5055.
- Biskobing DM. COPD and osteoporosis. Chest 2002; 121(2):609–20.